Oklo Q2 revenue reaches $1.2 million as loss widens

• Oklo reported Q2 2026 revenue of $1.2 million, above the roughly $83,800 analyst estimate, while its EPS loss widened to $0.28.
• The net loss increased to $48.5 million from $24.7 million a year earlier, while research and development spending reached $39.5 million.
• Oklo achieved first criticality at its Groves isotope test reactor and continued advancing regulatory work for its Aurora-INL powerhouse.

Oklo (NYSE:OKLO) reported Q2 2026 revenue of $1.2 million while recording a loss of $0.28 per share, compared with an analyst loss estimate of $0.16.

Revenue exceeded the roughly $83,800 consensus estimate, while net loss widened to $48.5 million from $24.7 million a year earlier.

Research and development expenses increased to $39.5 million from $11.5 million as Oklo continued investing in reactor, fuel and isotope development.

Oklo’s Groves Isotope Test Reactor achieved first criticality on August 6 after receiving DOE startup authorization in July, marking the first controlled chain reaction at the low-power facility.

The Groves facility reached criticality less than a year after groundbreaking and is intended to provide operating experience supporting Oklo’s planned commercial-scale isotope production facilities.

Oklo is separately advancing its Aurora powerhouse at Idaho National Laboratory, where DOE approved the project’s Preliminary Documented Safety Analysis in June under the Reactor Pilot Program.